PL3274349T3 - Cząstki N-(5-cyjano-4-((2-metoksetylo)amino)pirydin-2-ylo)-7-formylo-6-((4-metylo-2-oksopiperazyn-1-ylo)metylo)-3,4-dihydro-1,8-naftyrydyno-1(2H)-karboksyamidu - Google Patents
Cząstki N-(5-cyjano-4-((2-metoksetylo)amino)pirydin-2-ylo)-7-formylo-6-((4-metylo-2-oksopiperazyn-1-ylo)metylo)-3,4-dihydro-1,8-naftyrydyno-1(2H)-karboksyamiduInfo
- Publication number
- PL3274349T3 PL3274349T3 PL16712082T PL16712082T PL3274349T3 PL 3274349 T3 PL3274349 T3 PL 3274349T3 PL 16712082 T PL16712082 T PL 16712082T PL 16712082 T PL16712082 T PL 16712082T PL 3274349 T3 PL3274349 T3 PL 3274349T3
- Authority
- PL
- Poland
- Prior art keywords
- methyl
- oxopiperazin
- naphthyridine
- methoxyethyl
- carboxamide
- Prior art date
Links
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015000202 | 2015-03-25 | ||
| PCT/IB2016/051633 WO2016151500A1 (en) | 2015-03-25 | 2016-03-23 | Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide |
| EP16712082.3A EP3274349B1 (en) | 2015-03-25 | 2016-03-23 | Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3274349T3 true PL3274349T3 (pl) | 2020-10-05 |
Family
ID=55637404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16712082T PL3274349T3 (pl) | 2015-03-25 | 2016-03-23 | Cząstki N-(5-cyjano-4-((2-metoksetylo)amino)pirydin-2-ylo)-7-formylo-6-((4-metylo-2-oksopiperazyn-1-ylo)metylo)-3,4-dihydro-1,8-naftyrydyno-1(2H)-karboksyamidu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9802917B2 (enExample) |
| EP (1) | EP3274349B1 (enExample) |
| JP (1) | JP6696995B2 (enExample) |
| KR (1) | KR102606643B1 (enExample) |
| CN (1) | CN107406448B (enExample) |
| AR (1) | AR104060A1 (enExample) |
| AU (2) | AU2016238437B2 (enExample) |
| CA (1) | CA2977326C (enExample) |
| ES (1) | ES2803028T3 (enExample) |
| MX (1) | MX2017012293A (enExample) |
| PL (1) | PL3274349T3 (enExample) |
| RU (1) | RU2720456C2 (enExample) |
| TW (1) | TWI699206B (enExample) |
| WO (1) | WO2016151500A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2756748T3 (es) | 2014-10-03 | 2020-04-27 | Novartis Ag | Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4 |
| CN113105454B (zh) * | 2016-05-20 | 2022-10-11 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
| CN107619388A (zh) | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| EP3691616A1 (en) * | 2017-10-02 | 2020-08-12 | Novartis AG | Method for preparing a pharmaceutical product |
| CN110234649B (zh) * | 2017-10-31 | 2021-10-15 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂的盐、晶体、制备方法及其用途 |
| CN110225913B (zh) * | 2017-10-31 | 2021-10-15 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂晶型及其制备方法 |
| CN109745321B (zh) * | 2017-11-08 | 2022-04-29 | 上海翰森生物医药科技有限公司 | 包含fgfr4抑制剂的药物组合物 |
| EP3986405A4 (en) * | 2019-06-21 | 2023-06-14 | Terns Pharmaceuticals, Inc. | Compounds for inhibiting fgfr4 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420999D0 (en) | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| AU3633997A (en) | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| SK9192000A3 (en) | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| WO1999041239A1 (en) | 1998-02-10 | 1999-08-19 | Novartis Ag | B cell inhibitors |
| US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
| TW200305423A (en) | 2002-02-14 | 2003-11-01 | Ono Pharmaceutical Co | N-carbamoyl nitrogen-containing condensed ring compound and medicament containing same as active ingredient |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004056820A1 (en) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| CA2521619A1 (en) | 2003-04-11 | 2004-10-28 | Taigen Biotechnology | Aminoquinoline compounds |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| AU2006271781A1 (en) | 2005-07-15 | 2007-01-25 | F. Hoffmann-La Roche Ag | Novel heteroaryl fused cyclic amines |
| ME00011A (me) | 2005-12-21 | 2009-02-10 | Novartis Ag | Derivati pirimidinilaril uree kao fgf inhibitori |
| CA2635845A1 (en) | 2005-12-29 | 2007-07-12 | Janssen Pharmaceutica N.V. | Prokineticin 2 receptor antagonists |
| RU2008140144A (ru) | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| WO2007146230A2 (en) | 2006-06-14 | 2007-12-21 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
| JP2010520881A (ja) | 2007-03-09 | 2010-06-17 | ノバルティス アーゲー | 黒色腫の処置 |
| EP2234618A4 (en) | 2007-12-21 | 2011-04-27 | Scripps Research Inst | BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS |
| EP2341052A4 (en) | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
| EP2376085B1 (en) | 2008-12-19 | 2014-02-26 | Genentech, Inc. | Compounds and methods of use |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
| WO2011059839A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| ES2524548T3 (es) | 2009-10-30 | 2014-12-10 | Novartis Ag | N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea |
| EP2532656A1 (en) | 2010-02-01 | 2012-12-12 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
| SG193331A1 (en) | 2011-03-18 | 2013-10-30 | Lupin Ltd | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014079709A1 (en) | 2012-11-23 | 2014-05-30 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| TW201605452A (zh) | 2013-08-28 | 2016-02-16 | 安斯泰來製藥股份有限公司 | 以嘧啶化合物作爲有效成分之醫藥組成物 |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| CN105683188B (zh) * | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
-
2016
- 2016-03-18 US US15/073,766 patent/US9802917B2/en active Active
- 2016-03-23 MX MX2017012293A patent/MX2017012293A/es active IP Right Grant
- 2016-03-23 AR ARP160100792A patent/AR104060A1/es unknown
- 2016-03-23 WO PCT/IB2016/051633 patent/WO2016151500A1/en not_active Ceased
- 2016-03-23 CN CN201680018234.6A patent/CN107406448B/zh active Active
- 2016-03-23 RU RU2017133243A patent/RU2720456C2/ru active
- 2016-03-23 KR KR1020177026470A patent/KR102606643B1/ko active Active
- 2016-03-23 JP JP2017549754A patent/JP6696995B2/ja active Active
- 2016-03-23 EP EP16712082.3A patent/EP3274349B1/en active Active
- 2016-03-23 AU AU2016238437A patent/AU2016238437B2/en active Active
- 2016-03-23 ES ES16712082T patent/ES2803028T3/es active Active
- 2016-03-23 PL PL16712082T patent/PL3274349T3/pl unknown
- 2016-03-23 CA CA2977326A patent/CA2977326C/en active Active
- 2016-03-24 TW TW105109283A patent/TWI699206B/zh active
-
2019
- 2019-02-07 AU AU2019200936A patent/AU2019200936A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2720456C2 (ru) | 2020-04-30 |
| EP3274349A1 (en) | 2018-01-31 |
| CA2977326C (en) | 2023-08-29 |
| RU2017133243A (ru) | 2019-04-05 |
| AU2016238437B2 (en) | 2018-11-08 |
| BR112017016991A2 (pt) | 2018-04-10 |
| CN107406448B (zh) | 2021-03-09 |
| EP3274349B1 (en) | 2020-04-22 |
| CN107406448A (zh) | 2017-11-28 |
| JP6696995B2 (ja) | 2020-05-20 |
| ES2803028T3 (es) | 2021-01-22 |
| RU2017133243A3 (enExample) | 2019-07-29 |
| TW201641106A (zh) | 2016-12-01 |
| KR102606643B1 (ko) | 2023-11-28 |
| US9802917B2 (en) | 2017-10-31 |
| AU2016238437A1 (en) | 2017-08-17 |
| MX2017012293A (es) | 2018-01-09 |
| AR104060A1 (es) | 2017-06-21 |
| TWI699206B (zh) | 2020-07-21 |
| KR20170129758A (ko) | 2017-11-27 |
| CA2977326A1 (en) | 2016-09-29 |
| US20160304489A1 (en) | 2016-10-20 |
| AU2019200936A1 (en) | 2019-02-28 |
| WO2016151500A1 (en) | 2016-09-29 |
| JP2018509446A (ja) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276677B (en) | Naphthyridine compounds as jak kinase inhibitors | |
| IL291265A (en) | Selective jak1 inhibitors and their uses | |
| IL258052B (en) | Solid formations of isoquinolinone derivatives, process for their preparation, compositions containing them and methods of use | |
| PL3290418T3 (pl) | Inhibitory kinaz janusowych (jak) | |
| IL250158A0 (en) | History of naphthyridine and isoquinoline, their preparation and pharmaceutical preparations containing them | |
| ZA201704494B (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| SG11201610089QA (en) | Silicon nitride powder, silicon nitride sintered body and circuit substrate, and production method for said silicon nitride powder | |
| MX2017012293A (es) | Particulas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-fo rmil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-nafti ridina-1 (2h)-carboxamida. | |
| DK3881827T3 (en) | Formulering til administration af rna | |
| ZA201902710B (en) | Benzodiazolium compounds as enac inhibitors | |
| ZA201807080B (en) | Nicotine particles | |
| SI3345900T1 (sl) | 2,4-di(dušik-vsebujoča skupina)-substituirana pirimidinska spojina in postopek priprave ter uporaba le-te | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| ZA201805496B (en) | Somatostatin receptor antagonist compounds and methods of using the same | |
| IL263995A (en) | Innovative processes for making solvent guinilate cyclase stimulants | |
| SG10202100168XA (en) | Novel processes for preparation of soluble guanylate cyclase stimulators | |
| GB2547994B (en) | High velocity checkout terminal | |
| IL246973A0 (en) | History of pyrimidine imidazole amine, their preparation and pharmaceutical preparations containing them | |
| PL3228619T3 (pl) | Sposób wytwarzania apiksabanu | |
| PL3478684T3 (pl) | Nowe sposoby otrzymywania wemurafenibu | |
| IL257735B (en) | 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis | |
| IL248695B (en) | Poly(alkyl-2-cyanoacrylate) nanocapsules are highly loaded with the drug | |
| AU2016243V (en) | Ruby Falls Cercis canadensis | |
| GB201608238D0 (en) | Alkaloid-containing extracts from vachellia xanthophloea | |
| HK40004735A (en) | Novel jak1 selective inhibitors and uses thereof |